- Sticker Shock: What College Is Likely to Cost in 18 Years
- What Happened to Stocks? Most Unloved in 50 Years
- Many Greeks Moved Their Money Abroad Long Ago
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Marc Faber: 100% Chance of Global Recession
- Where Large Banks Fail, Regionals are Succeeding: Bove
- Main Players in the Greek Election
- Return to Drachma Risks Social Explosion: CEO
- What Would Greek Exit Mean for the US Economy?
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Top 20 European Stocks for Crisis Time: Strategist
- Curt Schilling’s Videogame Company Goes Bust
MOST SHARED
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Facebook IPO Fiasco: 10 Things Underwriters Got Wrong
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- More Fallout From the Facebook Fiasco
- Reum: Successfully Marketing Liquor through Facebook
- Greece to Exit Euro, New Currency to Fall 60%: Citi
- What College Tuition Will Look Like in 18 Years
- Marc Faber: 100% Chance of Global Recession
- What Every Investor Needs to Know About Greece
- Europe Stocks Close Broadly Flat on Greece Worries
MOST POPULAR
HOT ON FACEBOOK
Schering-Plough Beats Earnings Forecasts By Wide Margin
Text Size 
Schering-Plough [SGP
Loading...
()
] reported strong first-quarter results, surpassing consensus estimates by a wide margin due to strong sales of cholesterol drugs and allergy treatments.
Schering-Plough on Thursday morning announced first-quarter earnings growth of 55%, beating analysts' estimates on sharply higher sales of its prescription drugs, including two cholesterol fighters sold in partnership with Merck [MRK
Loading...
()
].
Profit rose 55% to $543 million, or 36 cents a share, from $350 million, or 24 cents a share, in the year-ago period.
Excluding one-time items, the Kenilworth, N.J.-based pharmaceutical company reported earnings of 42 cents a share. Analysts expected Schering-Plough to report 29 cents a share, according to Thomson Financial.
Sales in the period jumped 17% over last year to $3.0 billion before revenue from cholesterol drugs Vytorin and Zetia, which the drugmaker markets with Merck. Sales would have jumped 21% in the period including the co-marketed medicines.
Sales of allergy drugs Nasonex and Clarinex both came in above Wall Street estimates. The drugmaker also got a boost from arthritis treatment Remicade, which jumped 34% to $373 million in the first quarter. Schering-Plough sells Remicade outside of the U.S. and Japan under license from Johnson & Johnson [JNJ
Loading...
()
].
"This was largely a quality revenue-driven beat," said Tim Anderson, pharma analyst with Prudential Equity Group. "The 'whisper' was that Schering-Plough could beat by a significant margin, and they did. Other drug companies have also beat thus far this quarter, and those that have yet to report will probably beat as well."
- Former MLB pitcher Curt Schilling laid off the entire staff that formed his videogame company.
- Many states are moving to change the way taxpayers can challenge assessments from officials.
- The end to the Euro Zone crisis may be near but how it plays out is still a mystery, says this blogger.
- Google's 7-inch Android tablet is real and it’s clearly aimed at Amazon’s Kindle Fire, says Jon Fortt.
- For a mere $3 donation to help elect Mitt Romney, donors could be dining with Donald Trump.
- The founder of a liquor company tells how Facebook successfully markets his brand of spirits.
Data is a real-time snapshot *Data is delayed at least 15 minutes
